Kilitch Drugs Rectifies Board Meeting Outcome Typo

Kilitch Drugs India Ltd has submitted a rectification regarding a typographical error in the outcome of its Board meeting held on October 22, 2026. The error pertained to the conversion of outstanding debt of up to INR 57.00 crore into equity shares of its material subsidiary, Kilitch Estro Biotech PLC (KEB). The number of KEB equity shares to be allotted to the Company was corrected from 1,66,472 to 1,66,471, and the acquisition price per share was adjusted from INR 3,414 to INR 3,413.23. All other terms of the conversion remain unchanged.